Saturday, October 3, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· April 13, 2026

Navitas Semiconductor Appoints Gregory M. Fischer as Independent Director to its Board

View original at globenewswire.com
Navitas Semiconductor Appoints Gregory M…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Navitas has made great strides over the last year toward our mission of being the leader in high power semiconductors

    60% confidence
  • Fischer believes his extensive background in governance and industry leadership will further strengthen Navitas' foundation as they scale leading-edge GaN and high-voltage SiC technologies to high-power markets

    60% confidence
  • Navitas is the world's first semiconductor company to be CarbonNeutral-certified

    60% confidence
  • Greg is joining at a pivotal time for Navitas and adding his talent and experience to our current board is an important step in ensuring that Chris and our full management team have the support and access to key insights required for success in this highly competitive, fast moving market

    60% confidence
  • Navitas has over 300 patents issued or pending

    60% confidence
  • Navitas is capitalizing on the AI revolution and it is an exciting time to be part of the pivot to Navitas 2.0 as the Company leads the next generation of power semiconductors

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com